EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka, Takahiro Tsukioki, Hiroji Iwata, Fumikata Hara, Tomomi Fujisawa, Keita Sasaki, Ryo Sadachi, Riku Kajikawa, Takehiko Sakai und 10 weitere

Breast Cancer · 2026-07 · 33 (4) · 829-838

DOI: 10.1007/s12282-026-01846-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer, online erschienen am 16.04.2026. Verfasst von Kiyo Tanaka und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Okayama University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsAdultAgedFemaleHumansMiddle AgedErb-b2 Receptor Tyrosine KinasesNeoplasm MetastasisNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneTreatment OutcomeRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

De novo stage IV breast cancerDiscordance of treatment response between primary and metastatic sitesOverall survivalPrimary systemic therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Department of Breast Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
  • Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Department of Breast Surgery, Osaka Habikino Medical Center, Osaka, Japan.
  • Department of Breast Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
  • Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
  • Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya , Aichi, Japan.

Förderung

  • Okayama University

Zitieren

APA

Tanaka, K., Shimomura, A., Ishitobi, M., Yamanaka, T., Tsukioki, T., Iwata, H., Hara, F., Fujisawa, T., Sasaki, K., Sadachi, R., Kajikawa, R., Sakai, T., Sagara, Y., Shigematsu, H., Ozaki, Y., Nozawa, K., Sudo, K., Naito, Y., Terata, K., …, & Shien, T. (2026). Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast Cancer, 33(4), 829-838. https://doi.org/10.1007/s12282-026-01846-3

Vancouver

Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, et al. Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast Cancer. 2026;33(4):829-838. doi:10.1007/s12282-026-01846-3

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Kiyo and Shimomura, Akihiko and Ishitobi, Makoto and Yamanaka, Takashi and Tsukioki, Takahiro and Iwata, Hiroji and Hara, Fumikata and Fujisawa, Tomomi and Sasaki, Keita and Sadachi, Ryo and Kajikawa, Riku and Sakai, Takehiko and Sagara, Yasuaki and Shigematsu, Hideo and Ozaki, Yukinori and Nozawa, Kazuki and Sudo, Kazuki and Naito, Yoichi and Terata, Kaori and Ishiba, Toshiyuki and Fukuda, Haruhiko and Shien, Tadahiko},
  title = {Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017},
  journal = {Breast Cancer},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {829--838},
  doi = {10.1007/s12282-026-01846-3}
}
Kostenlos starten →